Ovarian Cancer diagnostics company, Cleo Diagnostics (ASX:COV), has received formal approval from the US National Cancer Institute to access blood samples held within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial biobank.
CLEO strengthens FDA submission following Access to globally recognised Biobank
June 25, 2025 Australian Biotech
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News
